Oxford Asset Management’s Blueprint Medicines BPMC Stock Holding History

Oxford Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-15,673	Closed	-$1.48M	–	1722
2019 Q2	$1.48M	Buy	+15,673	New	+$1.29M	0.03%	789
2018 Q4	–	Sell	-38,064	Closed	-$2.98M	–	1793
2018 Q3	$2.98M	Buy	38,064 +14,238	+60%	+$990K	0.06%	447
2018 Q2	$1.5M	Buy	+23,826	New	+$1.9M	0.03%	832
2018 Q1	–	Sell	-5,812	Closed	-$449K	–	1623
2017 Q4	$449K	Buy	+5,812	New	+$409K	0.01%	1210
2017 Q3	–	Sell	-5,039	Closed	-$255K	–	1533
2017 Q2	$255K	Sell	5,039 -38,700	-88%	-$1.64M	0.01%	1302
2017 Q1	$1.75M	Buy	+43,739	New	+$1.57M	0.04%	555
2016 Q4	–	Sell	-11,620	Closed	-$345K	–	771
2016 Q3	$345K	Buy	+11,620	New	+$289K	0.01%	654

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oxford Asset Management's BPMC Position: Q3 2019 in Review

Oxford Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 15,673 shares — an estimated $1.48M sold.

Oxford Asset Management first reported a position in BPMC in Q3 2016 and held it in 7 quarters. The position peaked at $2.98M in Q3 2018. 219 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

Oxford Asset Management reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 15,673 Blueprint Medicines shares in Q3 2019, an estimated $1.48M.
Oxford Asset Management first reported a position in Blueprint Medicines in Q3 2016 and held it in 7 quarters.
Oxford Asset Management's Blueprint Medicines position peaked at $2.98M in Q3 2018.
219 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.